NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis $1.18 -0.01 (-0.84%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About SELLAS Life Sciences Group Stock (NASDAQ:SLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SLS alerts:Sign Up Key Stats Today's Range$1.14▼$1.2150-Day Range$1.10▼$1.3552-Week Range$0.50▼$1.72Volume683,391 shsAverage Volume1.09 million shsMarket Capitalization$75.91 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Read More… Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade SELLAS Life Sciences Group Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks42nd Percentile Overall ScoreSLS MarketRank™: SELLAS Life Sciences Group scored higher than 42% of companies evaluated by MarketBeat, and ranked 736th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSELLAS Life Sciences Group has received no research coverage in the past 90 days.Read more about SELLAS Life Sciences Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.55) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about SELLAS Life Sciences Group's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.45% of the outstanding shares of SELLAS Life Sciences Group have been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently decreased by 25.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.45% of the outstanding shares of SELLAS Life Sciences Group have been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently decreased by 25.67%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.19 News SentimentSELLAS Life Sciences Group has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for SELLAS Life Sciences Group this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for SLS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by InstitutionsOnly 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address SLS Stock News HeadlinesSELLAS' Galinpepimut-S Gets Rare Pediatric Disease Designation For Treatment Of Pediatric AMLOctober 15, 2024 | markets.businessinsider.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid LeukemiaOctober 15, 2024 | globenewswire.comBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonOctober 31, 2024 | Porter & Company (Ad)Mubadala’s Kelix bio acquires GHH’s pharma assets to expand its life sciences portfolioOctober 14, 2024 | msn.comSELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | globenewswire.comSELLAS Life Sciences Gr (NASDAQ:SLS) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comSELLAS Life Sciences Gr (NASDAQ:SLS) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comBH Lynx SLS Mixes Softail & Full-Suspension Tech in Faster 80mm XC Race Mountain BikeSeptember 21, 2024 | yahoo.comSee More Headlines SLS Stock Analysis - Frequently Asked Questions How have SLS shares performed this year? SELLAS Life Sciences Group's stock was trading at $1.06 at the beginning of the year. Since then, SLS stock has increased by 11.3% and is now trading at $1.18. View the best growth stocks for 2024 here. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) posted its earnings results on Tuesday, August, 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. When did SELLAS Life Sciences Group's stock split? SELLAS Life Sciences Group shares reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SELLAS Life Sciences Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include (UNISQ) (UNISQ), Amgen (AMGN), Generex Biotechnology (GNBT), Salesforce (CRM), Bank of America (BAC), Bristol-Myers Squibb (BMY) and AbbVie (ABBV). Company Calendar Last Earnings8/13/2024Today10/31/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLS CUSIPN/A CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+154.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-17,349.61% Return on Assets-255.78% Debt Debt-to-Equity RatioN/A Current Ratio1.02 Quick Ratio1.02 Sales & Book Value Annual Sales$1 million Price / Sales75.91 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-4.72Miscellaneous Outstanding Shares64,332,000Free Float63,560,000Market Cap$75.91 million OptionableNot Optionable Beta2.39 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:SLS) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.